{"protocolSection": {"identificationModule": {"nctId": "NCT00660907", "orgStudyIdInfo": {"id": "D1690C00004"}, "organization": {"fullName": "AstraZeneca", "class": "INDUSTRY"}, "briefTitle": "Efficacy and Safety of Dapagliflozin in Combination With Metformin in Type 2 Diabetes Patients", "officialTitle": "A 52-Week International, Multi-centre, Randomised, Parallel-group, Double-blind, Active-controlled, Phase III Study With a 156-Week Extension Period to Evaluate the Efficacy and Safety of Dapagliflozin in Combination With Metformin Compared With Sulphonylurea in Combination With Metformin in Adult Patients With Type 2 Diabetes Who Have Inadequate Glycaemic Control on Metformin Therapy Alone."}, "statusModule": {"statusVerifiedDate": "2015-03", "overallStatus": "COMPLETED", "expandedAccessInfo": {"hasExpandedAccess": false}, "startDateStruct": {"date": "2008-03"}, "primaryCompletionDateStruct": {"date": "2009-12", "type": "ACTUAL"}, "completionDateStruct": {"date": "2013-01", "type": "ACTUAL"}, "studyFirstSubmitDate": "2008-04-15", "studyFirstSubmitQcDate": "2008-04-15", "studyFirstPostDateStruct": {"date": "2008-04-17", "type": "ESTIMATED"}, "resultsFirstSubmitDate": "2013-01-21", "resultsFirstSubmitQcDate": "2013-07-19", "resultsFirstPostDateStruct": {"date": "2013-08-23", "type": "ESTIMATED"}, "lastUpdateSubmitDate": "2015-03-10", "lastUpdatePostDateStruct": {"date": "2015-03-30", "type": "ESTIMATED"}}, "sponsorCollaboratorsModule": {"responsibleParty": {"type": "SPONSOR"}, "leadSponsor": {"name": "AstraZeneca", "class": "INDUSTRY"}, "collaborators": [{"name": "Bristol-Myers Squibb", "class": "INDUSTRY"}]}, "oversightModule": {"oversightHasDmc": false}, "descriptionModule": {"briefSummary": "This study is being carried out to see if dapagliflozin as an addition to metformin is effective and safe in treating patients with type 2 diabetes when compared to glipizide (sulphonylurea) as an addition to metformin treatment."}, "conditionsModule": {"conditions": ["Type 2 Diabetes"], "keywords": ["Dapagliflozin", "efficacy", "safety", "metformin", "Type 2 diabetes"]}, "designModule": {"studyType": "INTERVENTIONAL", "phases": ["PHASE3"], "designInfo": {"allocation": "RANDOMIZED", "interventionModel": "PARALLEL", "primaryPurpose": "TREATMENT", "maskingInfo": {"masking": "QUADRUPLE", "whoMasked": ["PARTICIPANT", "CARE_PROVIDER", "INVESTIGATOR", "OUTCOMES_ASSESSOR"]}}, "enrollmentInfo": {"count": 1217, "type": "ACTUAL"}}, "armsInterventionsModule": {"armGroups": [{"label": "1", "type": "EXPERIMENTAL", "description": "dapagliflozin plus metformin", "interventionNames": ["Drug: dapagliflozin", "Drug: metformin hydrochloride"]}, {"label": "2", "type": "ACTIVE_COMPARATOR", "description": "glipizide plus metformin", "interventionNames": ["Drug: glipizide", "Drug: metformin hydrochloride"]}], "interventions": [{"type": "DRUG", "name": "dapagliflozin", "description": "Tablet oral 2.5, 5, or 10 mg total daily dose once daily 208 weeks", "armGroupLabels": ["1"]}, {"type": "DRUG", "name": "glipizide", "description": "Capsule oral 5, 10, or 20 mg total daily dose once or split/twice daily 208 weeks", "armGroupLabels": ["2"], "otherNames": ["Glucotrol"]}, {"type": "DRUG", "name": "metformin hydrochloride", "description": "Tablet oral 1500, 2000, or 2500 mg total daily dose split/twice daily 218 weeks", "armGroupLabels": ["1", "2"], "otherNames": ["Glucophage"]}]}, "outcomesModule": {"primaryOutcomes": [{"measure": "Adjusted Mean Change in HbA1c Levels", "description": "To assess the effect of dapagliflozin plus metformin compared to glipizide plus metformin on the absolute change from baseline in HbA1c level after 52 weeks double-blind treatment in patients with type 2 diabetes who have inadequate glycaemic control on 1500 mg/day or higher doses of metformin therapy alone.", "timeFrame": "Baseline to Week 52"}], "secondaryOutcomes": [{"measure": "Adjusted Mean Change in Body Weight", "description": "To assess the effect of dapagliflozin plus metformin compared to glipizide plus metformin on body weight after 52 weeks double-blind treatment.", "timeFrame": "Baseline to Week 52"}, {"measure": "Proportion of Participants With at Least One Episode of Hypoglycemia", "description": "To assess the effect of dapagliflozin plus metformin treatment compared to glipizide plus metformin on the occurrence of hypoglycemic events. Least Squares Mean represents the percent of participants adjusted for HbA1c baseline value.", "timeFrame": "Baseline to Week 52"}, {"measure": "Proportion of Participants With Body Weight Reduction of at Least 5%", "description": "To evaluate the effect of dapagliflozin plus metformin compared to glipizide plus metformin on body weight assessed by a reduction after 52 weeks of at least 5% compared to baseline. Least Squares Mean represents the percent of participants adjusted for baseline value.", "timeFrame": "Baseline to Week 52"}]}, "eligibilityModule": {"eligibilityCriteria": "Inclusion Criteria:\n\n* Type 2 Diabetes\n* Treated with oral anti-diabetic drug therapy therapy including Metformin for at least 8 weeks prior to enrolment\n* HbA1c \\>6.5% and \\</=10%\n\nExclusion Criteria:\n\n* Type 1 Diabetes\n* Insulin therapy within one year of enrolment\n* Renal (kidney) failure or dysfunction", "healthyVolunteers": false, "sex": "ALL", "minimumAge": "18 Years", "stdAges": ["ADULT", "OLDER_ADULT"]}, "contactsLocationsModule": {"overallOfficials": [{"name": "Michael A. Nauck, Prof. Dr. med.", "affiliation": "Diabeteszentrum Bad Lauterberg, Germany", "role": "PRINCIPAL_INVESTIGATOR"}], "locations": [{"facility": "Research Site", "city": "Buenos Aires", "country": "Argentina", "geoPoint": {"lat": -34.61315, "lon": -58.37723}}, {"facility": "Research Site", "city": "Caba", "country": "Argentina", "geoPoint": {"lat": -34.61315, "lon": -58.37723}}, {"facility": "Research Site", "city": "Capital Federal", "country": "Argentina", "geoPoint": {"lat": -34.61315, "lon": -58.37723}}, {"facility": "Research Site", "city": "Ciudad de Buenos Aires", "country": "Argentina", "geoPoint": {"lat": -34.61315, "lon": -58.37723}}, {"facility": "Research Site", "city": "Corrientes", "country": "Argentina", "geoPoint": {"lat": -27.4806, "lon": -58.8341}}, {"facility": "Research Site", "city": "C\u00f3rdoba", "country": "Argentina", "geoPoint": {"lat": -31.4135, "lon": -64.18105}}, {"facility": "Research Site", "city": "La Plata", "country": "Argentina", "geoPoint": {"lat": -34.92145, "lon": -57.95453}}, {"facility": "Research Site", "city": "Rosario", "country": "Argentina", "geoPoint": {"lat": -32.94682, "lon": -60.63932}}, {"facility": "Research Site", "city": "Santa Fe", "country": "Argentina", "geoPoint": {"lat": -31.63333, "lon": -60.7}}, {"facility": "Research Site", "city": "L'aigle", "country": "France", "geoPoint": {"lat": 48.76216, "lon": 0.62746}}, {"facility": "Research Site", "city": "Murs Erigne", "country": "France", "geoPoint": {"lat": 47.4, "lon": -0.55}}, {"facility": "Research Site", "city": "Nantes Cedex 1", "country": "France", "geoPoint": {"lat": 47.21725, "lon": -1.55336}}, {"facility": "Research Site", "city": "Nantes", "country": "France", "geoPoint": {"lat": 47.21725, "lon": -1.55336}}, {"facility": "Research Site", "city": "Paris", "country": "France", "geoPoint": {"lat": 48.85341, "lon": 2.3488}}, {"facility": "Research Site", "city": "Tours", "country": "France", "geoPoint": {"lat": 47.38333, "lon": 0.68333}}, {"facility": "Research Site", "city": "Vannes", "country": "France", "geoPoint": {"lat": 47.66667, "lon": -2.75}}, {"facility": "Research Site", "city": "Bad Lauterberg", "country": "Germany"}, {"facility": "Research Site", "city": "Berlin", "country": "Germany", "geoPoint": {"lat": 52.52437, "lon": 13.41053}}, {"facility": "Research Site", "city": "Dresden", "country": "Germany", "geoPoint": {"lat": 51.05089, "lon": 13.73832}}, {"facility": "Research Site", "city": "Essen", "country": "Germany", "geoPoint": {"lat": 51.45657, "lon": 7.01228}}, {"facility": "Research Site", "city": "Frankfurt", "country": "Germany", "geoPoint": {"lat": 50.11552, "lon": 8.68417}}, {"facility": "Research Site", "city": "Hamburg", "country": "Germany", "geoPoint": {"lat": 53.57532, "lon": 10.01534}}, {"facility": "Research Site", "city": "Heilbronn", "country": "Germany", "geoPoint": {"lat": 49.13995, "lon": 9.22054}}, {"facility": "Research Site", "city": "Ludwigshafen", "country": "Germany", "geoPoint": {"lat": 49.48121, "lon": 8.44641}}, {"facility": "Research Site", "city": "Mainz", "country": "Germany", "geoPoint": {"lat": 49.98419, "lon": 8.2791}}, {"facility": "Research Site", "city": "Pirna", "country": "Germany", "geoPoint": {"lat": 50.95843, "lon": 13.93702}}, {"facility": "Research Site", "city": "Schmiedeberg", "country": "Germany", "geoPoint": {"lat": 50.83644, "lon": 13.67622}}, {"facility": "Research Site", "city": "Wangen", "country": "Germany", "geoPoint": {"lat": 48.72933, "lon": 9.61175}}, {"facility": "Research Site", "city": "Perugia", "country": "Italy", "geoPoint": {"lat": 43.1122, "lon": 12.38878}}, {"facility": "Research Site", "city": "Pisa", "country": "Italy", "geoPoint": {"lat": 43.70853, "lon": 10.4036}}, {"facility": "Research Site", "city": "Roma", "country": "Italy", "geoPoint": {"lat": 41.89193, "lon": 12.51133}}, {"facility": "Research Site", "city": "Acapulco", "country": "Mexico", "geoPoint": {"lat": 16.86336, "lon": -99.8901}}, {"facility": "Research Site", "city": "Guadalajara", "country": "Mexico", "geoPoint": {"lat": 20.66682, "lon": -103.39182}}, {"facility": "Research Site", "city": "M\u00e9xico", "country": "Mexico", "geoPoint": {"lat": 19.42847, "lon": -99.12766}}, {"facility": "Research Site", "city": "Veracruz", "country": "Mexico", "geoPoint": {"lat": 19.18095, "lon": -96.1429}}, {"facility": "Research Site", "city": "Den Haag", "country": "Netherlands", "geoPoint": {"lat": 52.07667, "lon": 4.29861}}, {"facility": "Research Site", "city": "Deurne", "country": "Netherlands", "geoPoint": {"lat": 51.46, "lon": 5.79722}}, {"facility": "Research Site", "city": "Gorinchem", "country": "Netherlands", "geoPoint": {"lat": 51.83652, "lon": 4.97243}}, {"facility": "Research Site", "city": "Groningen", "country": "Netherlands", "geoPoint": {"lat": 53.21917, "lon": 6.56667}}, {"facility": "Research Site", "city": "Lichtenvoorde (gld)", "country": "Netherlands"}, {"facility": "Research Site", "city": "Losser", "country": "Netherlands", "geoPoint": {"lat": 52.26083, "lon": 7.00417}}, {"facility": "Research Site", "city": "Poortvliet", "country": "Netherlands", "geoPoint": {"lat": 51.54417, "lon": 4.14306}}, {"facility": "Research Site", "city": "Rotterdam", "country": "Netherlands", "geoPoint": {"lat": 51.9225, "lon": 4.47917}}, {"facility": "Research Site", "city": "Wildervank", "country": "Netherlands", "geoPoint": {"lat": 53.08083, "lon": 6.8625}}, {"facility": "Research Site", "city": "Zutphen", "country": "Netherlands", "geoPoint": {"lat": 52.13833, "lon": 6.20139}}, {"facility": "Research Site", "city": "Cape Town", "country": "South Africa", "geoPoint": {"lat": -33.92584, "lon": 18.42322}}, {"facility": "Research Site", "city": "Durban", "country": "South Africa", "geoPoint": {"lat": -29.8579, "lon": 31.0292}}, {"facility": "Research Site", "city": "Johannesburg", "country": "South Africa", "geoPoint": {"lat": -26.20227, "lon": 28.04363}}, {"facility": "Research Site", "city": "Parow", "country": "South Africa", "geoPoint": {"lat": -33.89723, "lon": 18.59992}}, {"facility": "Research Site", "city": "Pretoria", "country": "South Africa", "geoPoint": {"lat": -25.74486, "lon": 28.18783}}, {"facility": "Research Site", "city": "Umkomaas", "country": "South Africa", "geoPoint": {"lat": -30.20674, "lon": 30.79776}}, {"facility": "Research Site", "city": "Witbank", "country": "South Africa", "geoPoint": {"lat": -25.87133, "lon": 29.23323}}, {"facility": "Research Site", "city": "Alicante", "country": "Spain", "geoPoint": {"lat": 38.34517, "lon": -0.48149}}, {"facility": "Research Site", "city": "Alzira (Valencia)", "country": "Spain"}, {"facility": "Research Site", "city": "Barcelona", "country": "Spain", "geoPoint": {"lat": 41.38879, "lon": 2.15899}}, {"facility": "Research Site", "city": "Cornell\u00e1 de Llobregat (BCN)", "country": "Spain"}, {"facility": "Research Site", "city": "Madrid", "country": "Spain", "geoPoint": {"lat": 40.4165, "lon": -3.70256}}, {"facility": "Research Site", "city": "Sevilla", "country": "Spain", "geoPoint": {"lat": 37.38283, "lon": -5.97317}}, {"facility": "Research Site", "city": "G\u00f6teborg", "country": "Sweden", "geoPoint": {"lat": 57.70716, "lon": 11.96679}}, {"facility": "Research Site", "city": "J\u00e4rf\u00e4lla", "country": "Sweden"}, {"facility": "Research Site", "city": "Lund", "country": "Sweden", "geoPoint": {"lat": 55.70584, "lon": 13.19321}}, {"facility": "Research Site", "city": "Malm\u00f6", "country": "Sweden", "geoPoint": {"lat": 55.60587, "lon": 13.00073}}, {"facility": "Research Site", "city": "Skene", "country": "Sweden", "geoPoint": {"lat": 57.48995, "lon": 12.64196}}, {"facility": "Research Site", "city": "Stockholm", "country": "Sweden", "geoPoint": {"lat": 59.33258, "lon": 18.0649}}, {"facility": "Research Site", "city": "S\u00f6dert\u00e4lje", "country": "Sweden", "geoPoint": {"lat": 59.19554, "lon": 17.62525}}, {"facility": "Research Site", "city": "Ume\u00e5", "country": "Sweden", "geoPoint": {"lat": 63.82842, "lon": 20.25972}}, {"facility": "Research Site", "city": "Addlestone", "country": "United Kingdom", "geoPoint": {"lat": 51.37135, "lon": -0.49353}}, {"facility": "Research Site", "city": "Aylesbury", "country": "United Kingdom", "geoPoint": {"lat": 51.81665, "lon": -0.81458}}, {"facility": "Research Site", "city": "Bath", "country": "United Kingdom", "geoPoint": {"lat": 51.3751, "lon": -2.36172}}, {"facility": "Research Site", "city": "Bolton", "country": "United Kingdom", "geoPoint": {"lat": 53.58333, "lon": -2.43333}}, {"facility": "Research Site", "city": "Bury St Edmonds", "country": "United Kingdom"}, {"facility": "Research Site", "city": "Cookstown", "country": "United Kingdom", "geoPoint": {"lat": 54.64305, "lon": -6.74595}}, {"facility": "Research Site", "city": "Coventry", "country": "United Kingdom", "geoPoint": {"lat": 52.40656, "lon": -1.51217}}, {"facility": "Research Site", "city": "Ecclesfield", "country": "United Kingdom", "geoPoint": {"lat": 53.43975, "lon": -1.4652}}, {"facility": "Research Site", "city": "Edinburgh", "country": "United Kingdom", "geoPoint": {"lat": 55.95206, "lon": -3.19648}}, {"facility": "Research Site", "city": "Mortimer Reading", "country": "United Kingdom"}, {"facility": "Research Site", "city": "Trowbridge", "country": "United Kingdom", "geoPoint": {"lat": 51.31889, "lon": -2.20861}}]}, "referencesModule": {"references": [{"pmid": "21816980", "type": "RESULT", "citation": "Nauck MA, Del Prato S, Meier JJ, Duran-Garcia S, Rohwedder K, Elze M, Parikh SJ. Dapagliflozin versus glipizide as add-on therapy in patients with type 2 diabetes who have inadequate glycemic control with metformin: a randomized, 52-week, double-blind, active-controlled noninferiority trial. Diabetes Care. 2011 Sep;34(9):2015-22. doi: 10.2337/dc11-0606. Epub 2011 Aug 4."}, {"pmid": "23529570", "type": "DERIVED", "citation": "Nauck M, del Prato S, Meier JJ, Duran-Garcia S, Rohwedder K, Elze M, Parikh SJ. [Dapagliflozin versus glipizide as add-on therapy in patients with type 2 diabetes who have inadequate glycemic control with metformin]. Dtsch Med Wochenschr. 2013 Apr;138 Suppl 1:S6-15. doi: 10.1055/s-0032-1305283. Epub 2013 Mar 25. German."}], "seeAlsoLinks": [{"label": "CSR-D1690C00004.pdf", "url": "http://filehosting.pharmacm.com/DownloadService.ashx?client=CTR_MED_6111&studyid=289&filename=CSR-D1690C00004.pdf"}]}}, "resultsSection": {"participantFlowModule": {"preAssignmentDetails": "For participants with a metformin dose of less than 1500 mg/day, a change in metformin dose in the past 8 weeks or on an Oral Anti-Diabetic (OAD), an 8-week metformin-only dose stabilisation period occurred. A 2-week placebo lead in period occurred after the dose stabilisation period or after enrolment if dose stabilisation period was skipped.", "recruitmentDetails": "The 1st patient was enrolled on 31 Mar 2008. The last patient last visit was on 15 Dec 2009. 1901 patients (pts) were screened and 1217 pts were enrolled with the aim to randomize 816. 2 randomized pts were excluded since they received no medication. Eventually, 814 pts received medication. This study was conducted at 95 centers world-wide.", "groups": [{"id": "FG000", "title": "Dapagliflozin Plus Metformin", "description": "Experimental dapagliflozin plus metformin"}, {"id": "FG001", "title": "Glipizide Plus Metformin", "description": "Active Comparator glipizide plus metformin"}], "periods": [{"title": "Overall Study", "milestones": [{"type": "STARTED", "achievements": [{"groupId": "FG000", "comment": "Of the 406 randomized participants only 400 were included in the full analysis set.", "numSubjects": "406"}, {"groupId": "FG001", "comment": "Of the 408 randomized participants only 401 were included in the full analysis set.", "numSubjects": "408"}]}, {"type": "COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "322"}, {"groupId": "FG001", "numSubjects": "314"}]}, {"type": "NOT COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "84"}, {"groupId": "FG001", "numSubjects": "94"}]}], "dropWithdraws": [{"type": "Incorrect Enrollment", "reasons": [{"groupId": "FG000", "numSubjects": "1"}, {"groupId": "FG001", "numSubjects": "1"}]}, {"type": "Adverse Event", "reasons": [{"groupId": "FG000", "numSubjects": "33"}, {"groupId": "FG001", "numSubjects": "19"}]}, {"type": "Subject No Longer Meets Study Criteria", "reasons": [{"groupId": "FG000", "numSubjects": "6"}, {"groupId": "FG001", "numSubjects": "27"}]}, {"type": "Withdrawal by Subject", "reasons": [{"groupId": "FG000", "numSubjects": "23"}, {"groupId": "FG001", "numSubjects": "32"}]}, {"type": "Lost to Follow-up", "reasons": [{"groupId": "FG000", "numSubjects": "3"}, {"groupId": "FG001", "numSubjects": "3"}]}, {"type": "Poor/Non-Compliance", "reasons": [{"groupId": "FG000", "numSubjects": "5"}, {"groupId": "FG001", "numSubjects": "1"}]}, {"type": "Safety", "reasons": [{"groupId": "FG000", "numSubjects": "1"}, {"groupId": "FG001", "numSubjects": "0"}]}, {"type": "Death", "reasons": [{"groupId": "FG000", "numSubjects": "1"}, {"groupId": "FG001", "numSubjects": "3"}]}, {"type": "Various", "reasons": [{"groupId": "FG000", "numSubjects": "11"}, {"groupId": "FG001", "numSubjects": "8"}]}]}]}, "baselineCharacteristicsModule": {"populationDescription": "Full Analysis Set defined as all randomized participants (as randomized) who received at least one dose of double-blind study medication, who have a non-missing baseline value and at least one post-baseline efficacy value for at least one efficacy variable during double-blind treatment period.", "groups": [{"id": "BG000", "title": "Dapagliflozin Plus Metformin", "description": "Experimental dapagliflozin plus metformin"}, {"id": "BG001", "title": "Glipizide Plus Metformin", "description": "Active Comparator glipizide plus metformin"}, {"id": "BG002", "title": "Total", "description": "Total of all reporting groups"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "BG000", "value": "400"}, {"groupId": "BG001", "value": "401"}, {"groupId": "BG002", "value": "801"}]}], "measures": [{"title": "Age, Continuous", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "years", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "58.1", "spread": "9.37"}, {"groupId": "BG001", "value": "58.6", "spread": "9.80"}, {"groupId": "BG002", "value": "58.4", "spread": "9.58"}]}]}]}, {"title": "Sex: Female, Male", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"categories": [{"title": "Female", "measurements": [{"groupId": "BG000", "value": "179"}, {"groupId": "BG001", "value": "181"}, {"groupId": "BG002", "value": "360"}]}, {"title": "Male", "measurements": [{"groupId": "BG000", "value": "221"}, {"groupId": "BG001", "value": "220"}, {"groupId": "BG002", "value": "441"}]}]}]}, {"title": "Race/Ethnicity, Customized", "paramType": "NUMBER", "unitOfMeasure": "Participants", "classes": [{"title": "American Indian or Alaska Native", "categories": [{"measurements": [{"groupId": "BG000", "value": "0"}, {"groupId": "BG001", "value": "0"}, {"groupId": "BG002", "value": "0"}]}]}, {"title": "Asian", "categories": [{"measurements": [{"groupId": "BG000", "value": "27"}, {"groupId": "BG001", "value": "34"}, {"groupId": "BG002", "value": "61"}]}]}, {"title": "Native Hawaiian or Other Pacific Islander", "categories": [{"measurements": [{"groupId": "BG000", "value": "0"}, {"groupId": "BG001", "value": "0"}, {"groupId": "BG002", "value": "0"}]}]}, {"title": "Black or African American", "categories": [{"measurements": [{"groupId": "BG000", "value": "26"}, {"groupId": "BG001", "value": "24"}, {"groupId": "BG002", "value": "50"}]}]}, {"title": "White", "categories": [{"measurements": [{"groupId": "BG000", "value": "327"}, {"groupId": "BG001", "value": "323"}, {"groupId": "BG002", "value": "650"}]}]}, {"title": "More than one race", "categories": [{"measurements": [{"groupId": "BG000", "value": "0"}, {"groupId": "BG001", "value": "0"}, {"groupId": "BG002", "value": "0"}]}]}, {"title": "Unknown or Not Reported", "categories": [{"measurements": [{"groupId": "BG000", "value": "20"}, {"groupId": "BG001", "value": "20"}, {"groupId": "BG002", "value": "40"}]}]}]}, {"title": "BMI", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "kg/m2", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "31.71", "spread": "5.104"}, {"groupId": "BG001", "value": "31.23", "spread": "5.053"}, {"groupId": "BG002", "value": "31.47", "spread": "5.081"}]}]}]}, {"title": "HbA1c", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "percent", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "7.69", "spread": "0.855"}, {"groupId": "BG001", "value": "7.74", "spread": "0.886"}, {"groupId": "BG002", "value": "7.72", "spread": "0.870"}]}]}]}, {"title": "FPG", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "ng/mL", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "162.24", "spread": "37.796"}, {"groupId": "BG001", "value": "163.91", "spread": "41.559"}, {"groupId": "BG002", "value": "163.07", "spread": "39.708"}]}]}]}]}, "outcomeMeasuresModule": {"outcomeMeasures": [{"type": "PRIMARY", "title": "Adjusted Mean Change in HbA1c Levels", "description": "To assess the effect of dapagliflozin plus metformin compared to glipizide plus metformin on the absolute change from baseline in HbA1c level after 52 weeks double-blind treatment in patients with type 2 diabetes who have inadequate glycaemic control on 1500 mg/day or higher doses of metformin therapy alone.", "populationDescription": "Full Analysis Set, participants with non-missing baseline and Week 52 (LOCF) values", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "95% Confidence Interval", "unitOfMeasure": "percent", "timeFrame": "Baseline to Week 52", "groups": [{"id": "OG000", "title": "Dapagliflozin Plus Metformin", "description": "Experimental dapagliflozin plus metformin"}, {"id": "OG001", "title": "Glipizide Plus Metformin", "description": "Active Comparator glipizide plus metformin"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "400"}, {"groupId": "OG001", "value": "401"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "-0.52", "lowerLimit": "-0.60", "upperLimit": "-0.44"}, {"groupId": "OG001", "value": "-0.52", "lowerLimit": "-0.60", "upperLimit": "-0.44"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "groupDescription": "The null hypothesis is given as H0: mean(treat) minus mean(reference) \\>= delta versus the alternative HA: mean(treat) minus mean(reference) \\< delta (with alpha = 0.025, one-sided)", "testedNonInferiority": true, "nonInferiorityType": "NON_INFERIORITY_OR_EQUIVALENCE", "nonInferiorityComment": "non-inferior margin delta = 0.35", "pValue": "<0.0001", "pValueComment": "Significant at alpha=0.025 (1-sided). A hierarchical closed testing procedure was used to control Type I error across the primary \\& key secondary objectives", "statisticalMethod": "ANCOVA", "statisticalComment": "with treatment group as effect and baseline value as covariate", "paramType": "Mean Difference (Final Values)", "paramValue": "0.00", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-0.11", "ciUpperLimit": "0.11", "dispersionType": "STANDARD_ERROR_OF_MEAN", "dispersionValue": "0.0569"}]}, {"type": "SECONDARY", "title": "Adjusted Mean Change in Body Weight", "description": "To assess the effect of dapagliflozin plus metformin compared to glipizide plus metformin on body weight after 52 weeks double-blind treatment.", "populationDescription": "Full Analysis Set, participants with non-missing baseline and Week 52 (LOCF) values", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "95% Confidence Interval", "unitOfMeasure": "kg", "timeFrame": "Baseline to Week 52", "groups": [{"id": "OG000", "title": "Dapagliflozin Plus Metformin", "description": "Experimental dapagliflozin plus metformin"}, {"id": "OG001", "title": "Glipizide Plus Metformin", "description": "Active Comparator glipizide plus metformin"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "400"}, {"groupId": "OG001", "value": "401"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "-3.22", "lowerLimit": "-3.56", "upperLimit": "-2.87"}, {"groupId": "OG001", "value": "1.44", "lowerLimit": "1.09", "upperLimit": "1.78"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "groupDescription": "H0: mean(treat) minus mean(reference) = 0 versus the alternative HA: mean(treat) minus mean(reference) =/= 0", "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "<0.0001", "pValueComment": "Significant at alpha=0.05 (2-sided). Key secondary endpoints are tested following a hierarchical closed testing procedure", "statisticalMethod": "ANCOVA", "statisticalComment": "with treatment group as effect and baseline value as covariate", "paramType": "Mean Difference (Final Values)", "paramValue": "-4.65", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-5.14", "ciUpperLimit": "-4.17", "dispersionType": "STANDARD_ERROR_OF_MEAN", "dispersionValue": "0.2483"}]}, {"type": "SECONDARY", "title": "Proportion of Participants With at Least One Episode of Hypoglycemia", "description": "To assess the effect of dapagliflozin plus metformin treatment compared to glipizide plus metformin on the occurrence of hypoglycemic events. Least Squares Mean represents the percent of participants adjusted for HbA1c baseline value.", "populationDescription": "Full analysis set", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "95% Confidence Interval", "unitOfMeasure": "Percentage of participants", "timeFrame": "Baseline to Week 52", "groups": [{"id": "OG000", "title": "Dapagliflozin Plus Metformin", "description": "Experimental dapagliflozin plus metformin"}, {"id": "OG001", "title": "Glipizide Plus Metformin", "description": "Active Comparator glipizide plus metformin"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "400"}, {"groupId": "OG001", "value": "401"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "3.5", "lowerLimit": "1.7", "upperLimit": "5.3"}, {"groupId": "OG001", "value": "40.8", "lowerLimit": "36.1", "upperLimit": "45.5"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "groupDescription": "H0: proportion(treat) minus proportion(reference) = 0 versus the alternative HA: proportion(treat) minus proportion(reference) =/= 0", "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "<0.0001", "pValueComment": "Significant at alpha=0.05 (2-sided). Key secondary endpoints are tested following a hierarchical closed testing procedure", "statisticalMethod": "Regression, Logistic", "statisticalComment": "Based on methodology of Zhang, Tsiatis \\& Davidian and Davidian, Tsiatis, Zhang \\& Lu, with adjustment for baseline value.", "paramType": "Risk Difference (RD)", "paramValue": "-37.2", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-42.3", "ciUpperLimit": "-32.2", "dispersionType": "STANDARD_ERROR_OF_MEAN", "dispersionValue": "2.578"}]}, {"type": "SECONDARY", "title": "Proportion of Participants With Body Weight Reduction of at Least 5%", "description": "To evaluate the effect of dapagliflozin plus metformin compared to glipizide plus metformin on body weight assessed by a reduction after 52 weeks of at least 5% compared to baseline. Least Squares Mean represents the percent of participants adjusted for baseline value.", "populationDescription": "Full Analysis Set, participants with non-missing baseline and Week 52 (LOCF) values", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "95% Confidence Interval", "unitOfMeasure": "Percentage of participants", "timeFrame": "Baseline to Week 52", "groups": [{"id": "OG000", "title": "Dapagliflozin Plus Metformin", "description": "Experimental dapagliflozin plus metformin"}, {"id": "OG001", "title": "Glipizide Plus Metformin", "description": "Active Comparator glipizide plus metformin"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "400"}, {"groupId": "OG001", "value": "401"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "33.3", "lowerLimit": "28.7", "upperLimit": "37.9"}, {"groupId": "OG001", "value": "2.5", "lowerLimit": "1.0", "upperLimit": "4.0"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "groupDescription": "H0: proportion(treat) minus proportion(reference) = 0 versus the alternative HA: proportion(treat) minus proportion(reference) =/= 0", "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "<0.0001", "pValueComment": "Significant at alpha=0.05 (2-sided). Key secondary endpoints are tested following a hierarchical closed testing procedure", "statisticalMethod": "Regression, Logistic", "statisticalComment": "Based on methodology of Zhang, Tsiatis \\& Davidian and Davidian, Tsiatis, Zhang \\& Lu, with adjustment for baseline value.", "paramType": "Risk Difference (RD)", "paramValue": "30.8", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "26.0", "ciUpperLimit": "35.7", "dispersionType": "STANDARD_ERROR_OF_MEAN", "dispersionValue": "2.480"}]}]}, "adverseEventsModule": {"frequencyThreshold": "5", "timeFrame": "Non-serious / serious adverse events on or after the first day and on or prior to the last day of the 52-week double-blind treatment plus 4/30 days or up to follow-up visit if earlier, or up to and including the start date of extension period if earlier.", "description": "Participants were questioned at each study visit about the occurrence of any health problems and any examination conducted at a study visit was assessed in comparison to the status at study entry.", "eventGroups": [{"id": "EG000", "title": "Dapagliflozin Plus Metformin", "description": "Experimental dapagliflozin plus metformin", "seriousNumAffected": 35, "seriousNumAtRisk": 406, "otherNumAffected": 163, "otherNumAtRisk": 406}, {"id": "EG001", "title": "Glipizide Plus Metformin", "description": "Active Comparator glipizide plus metformin", "seriousNumAffected": 46, "seriousNumAtRisk": 408, "otherNumAffected": 260, "otherNumAtRisk": 408}], "seriousEvents": [{"term": "Anaemia", "organSystem": "Blood and lymphatic system disorders", "sourceVocabulary": "MedDRA 12.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 406}, {"groupId": "EG001", "numAffected": 2, "numAtRisk": 408}]}, {"term": "Myocardial Infarction", "organSystem": "Cardiac disorders", "sourceVocabulary": "MedDRA 12.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 406}, {"groupId": "EG001", "numAffected": 3, "numAtRisk": 408}]}, {"term": "Acute Coronary Syndrome", "organSystem": "Cardiac disorders", "sourceVocabulary": "MedDRA 12.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 406}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 408}]}, {"term": "Acute Myocardial Infarction", "organSystem": "Cardiac disorders", "sourceVocabulary": "MedDRA 12.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 406}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 408}]}, {"term": "Angina Pectoris", "organSystem": "Cardiac disorders", "sourceVocabulary": "MedDRA 12.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 406}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 408}]}, {"term": "Atrial Fibrillation", "organSystem": "Cardiac disorders", "sourceVocabulary": "MedDRA 12.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 406}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 408}]}, {"term": "Atrioventricular Block Complete", "organSystem": "Cardiac disorders", "sourceVocabulary": "MedDRA 12.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 406}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 408}]}, {"term": "Bradycardia", "organSystem": "Cardiac disorders", "sourceVocabulary": "MedDRA 12.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 406}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 408}]}, {"term": "Cardiac Arrest", "organSystem": "Cardiac disorders", "sourceVocabulary": "MedDRA 12.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 406}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 408}]}, {"term": "Cardiac Failure", "organSystem": "Cardiac disorders", "sourceVocabulary": "MedDRA 12.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 406}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 408}]}, {"term": "Cardiac Failure Congestive", "organSystem": "Cardiac disorders", "sourceVocabulary": "MedDRA 12.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 406}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 408}]}, {"term": "Coronary Artery Disease", "organSystem": "Cardiac disorders", "sourceVocabulary": "MedDRA 12.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 406}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 408}]}, {"term": "Left Ventricular Failure", "organSystem": "Cardiac disorders", "sourceVocabulary": "MedDRA 12.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 406}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 408}]}, {"term": "Ventricular Arrhythmia", "organSystem": "Cardiac disorders", "sourceVocabulary": "MedDRA 12.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 406}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 408}]}, {"term": "Cataract", "organSystem": "Eye disorders", "sourceVocabulary": "MedDRA 12.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 406}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 408}]}, {"term": "Retinal Detachment", "organSystem": "Eye disorders", "sourceVocabulary": "MedDRA 12.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 406}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 408}]}, {"term": "Abdominal Pain", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA 12.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 406}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 408}]}, {"term": "Abdominal Pain Upper", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA 12.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 406}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 408}]}, {"term": "Anal Fissure", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA 12.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 406}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 408}]}, {"term": "Constipation", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA 12.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 406}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 408}]}, {"term": "Dyspepsia", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA 12.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 406}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 408}]}, {"term": "Gastritis", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA 12.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 406}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 408}]}, {"term": "Haemorrhoids", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA 12.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 406}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 408}]}, {"term": "Upper Gastrointestinal Haemorrhage", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA 12.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 406}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 408}]}, {"term": "Chest Pain", "organSystem": "General disorders", "sourceVocabulary": "MedDRA 12.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 406}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 408}]}, {"term": "Non-Cardiac Chest Pain", "organSystem": "General disorders", "sourceVocabulary": "MedDRA 12.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 406}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 408}]}, {"term": "Sudden Death", "organSystem": "General disorders", "sourceVocabulary": "MedDRA 12.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 406}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 408}]}, {"term": "Cholecystitis", "organSystem": "Hepatobiliary disorders", "sourceVocabulary": "MedDRA 12.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 406}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 408}]}, {"term": "Cholecystitis Acute", "organSystem": "Hepatobiliary disorders", "sourceVocabulary": "MedDRA 12.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 406}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 408}]}, {"term": "Cholelithiasis", "organSystem": "Hepatobiliary disorders", "sourceVocabulary": "MedDRA 12.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 406}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 408}]}, {"term": "Hepatic Cirrhosis", "organSystem": "Hepatobiliary disorders", "sourceVocabulary": "MedDRA 12.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 406}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 408}]}, {"term": "Diverticulitis", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 12.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 406}, {"groupId": "EG001", "numAffected": 2, "numAtRisk": 408}]}, {"term": "Bronchitis", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 12.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 406}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 408}]}, {"term": "Erysipelas", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 12.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 406}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 408}]}, {"term": "Gastroenteritis", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 12.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 406}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 408}]}, {"term": "Gastroenteritis Viral", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 12.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 406}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 408}]}, {"term": "Liver Abscess", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 12.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 406}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 408}]}, {"term": "Lower Respiratory Tract Infection", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 12.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 406}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 408}]}, {"term": "Pneumonia", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 12.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 406}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 408}]}, {"term": "Pyelonephritis", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 12.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 406}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 408}]}, {"term": "Sepsis", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 12.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 406}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 408}]}, {"term": "Septic Shock", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 12.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 406}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 408}]}, {"term": "Overdose", "organSystem": "Injury, poisoning and procedural complications", "sourceVocabulary": "MedDRA 12.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 406}, {"groupId": "EG001", "numAffected": 2, "numAtRisk": 408}]}, {"term": "Ankle Fracture", "organSystem": "Injury, poisoning and procedural complications", "sourceVocabulary": "MedDRA 12.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 406}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 408}]}, {"term": "Clavicle Fracture", "organSystem": "Injury, poisoning and procedural complications", "sourceVocabulary": "MedDRA 12.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 406}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 408}]}, {"term": "Contusion", "organSystem": "Injury, poisoning and procedural complications", "sourceVocabulary": "MedDRA 12.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 406}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 408}]}, {"term": "Humerus Fracture", "organSystem": "Injury, poisoning and procedural complications", "sourceVocabulary": "MedDRA 12.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 406}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 408}]}, {"term": "Multiple Injuries", "organSystem": "Injury, poisoning and procedural complications", "sourceVocabulary": "MedDRA 12.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 406}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 408}]}, {"term": "Postoperative Renal Failure", "organSystem": "Injury, poisoning and procedural complications", "sourceVocabulary": "MedDRA 12.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 406}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 408}]}, {"term": "Road Traffic Accident", "organSystem": "Injury, poisoning and procedural complications", "sourceVocabulary": "MedDRA 12.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 406}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 408}]}, {"term": "Wrist Fracture", "organSystem": "Injury, poisoning and procedural complications", "sourceVocabulary": "MedDRA 12.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 406}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 408}]}, {"term": "Creatinine Renal Clearance Decreased", "organSystem": "Investigations", "sourceVocabulary": "MedDRA 12.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 406}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 408}]}, {"term": "Hypoglycaemia", "organSystem": "Metabolism and nutrition disorders", "sourceVocabulary": "MedDRA 12.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 406}, {"groupId": "EG001", "numAffected": 3, "numAtRisk": 408}]}, {"term": "Hyponatraemia", "organSystem": "Metabolism and nutrition disorders", "sourceVocabulary": "MedDRA 12.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 406}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 408}]}, {"term": "Arthralgia", "organSystem": "Musculoskeletal and connective tissue disorders", "sourceVocabulary": "MedDRA 12.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 406}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 408}]}, {"term": "Intervertebral Disc Protrusion", "organSystem": "Musculoskeletal and connective tissue disorders", "sourceVocabulary": "MedDRA 12.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 406}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 408}]}, {"term": "Rotator Cuff Syndrome", "organSystem": "Musculoskeletal and connective tissue disorders", "sourceVocabulary": "MedDRA 12.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 406}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 408}]}, {"term": "Prostate Cancer", "organSystem": "Neoplasms benign, malignant and unspecified (incl cysts and polyps)", "sourceVocabulary": "MedDRA 12.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 3, "numAtRisk": 406}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 408}]}, {"term": "Basal Cell Carcinoma", "organSystem": "Neoplasms benign, malignant and unspecified (incl cysts and polyps)", "sourceVocabulary": "MedDRA 12.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 406}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 408}]}, {"term": "Breast Cancer", "organSystem": "Neoplasms benign, malignant and unspecified (incl cysts and polyps)", "sourceVocabulary": "MedDRA 12.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 406}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 408}]}, {"term": "Bronchial Carcinoma", "organSystem": "Neoplasms benign, malignant and unspecified (incl cysts and polyps)", "sourceVocabulary": "MedDRA 12.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 406}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 408}]}, {"term": "Carotid Artery Stenosis", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA 12.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 406}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 408}]}, {"term": "Cerebral Thrombosis", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA 12.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 406}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 408}]}, {"term": "Cervicobrachial Syndrome", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA 12.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 406}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 408}]}, {"term": "Loss Of Consciousness", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA 12.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 406}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 408}]}, {"term": "Migraine", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA 12.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 406}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 408}]}, {"term": "Transient Ischaemic Attack", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA 12.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 406}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 408}]}, {"term": "Depression Suicidal", "organSystem": "Psychiatric disorders", "sourceVocabulary": "MedDRA 12.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 406}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 408}]}, {"term": "Obsessive-Compulsive Disorder", "organSystem": "Psychiatric disorders", "sourceVocabulary": "MedDRA 12.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 406}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 408}]}, {"term": "Diabetic Nephropathy", "organSystem": "Renal and urinary disorders", "sourceVocabulary": "MedDRA 12.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 406}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 408}]}, {"term": "Nephrolithiasis", "organSystem": "Renal and urinary disorders", "sourceVocabulary": "MedDRA 12.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 406}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 408}]}, {"term": "Urinary Incontinence", "organSystem": "Renal and urinary disorders", "sourceVocabulary": "MedDRA 12.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 406}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 408}]}, {"term": "Uterine Prolapse", "organSystem": "Reproductive system and breast disorders", "sourceVocabulary": "MedDRA 12.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 2, "numAtRisk": 406}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 408}]}, {"term": "Alveolitis Allergic", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA 12.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 406}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 408}]}, {"term": "Asthma", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA 12.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 406}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 408}]}, {"term": "Pulmonary Embolism", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA 12.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 406}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 408}]}, {"term": "Angioedema", "organSystem": "Skin and subcutaneous tissue disorders", "sourceVocabulary": "MedDRA 12.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 406}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 408}]}, {"term": "Urticaria", "organSystem": "Skin and subcutaneous tissue disorders", "sourceVocabulary": "MedDRA 12.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 406}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 408}]}], "otherEvents": [{"term": "Diarrhoea", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA 12.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 19, "numAtRisk": 406}, {"groupId": "EG001", "numAffected": 26, "numAtRisk": 408}]}, {"term": "Nasopharyngitis", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 12.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 43, "numAtRisk": 406}, {"groupId": "EG001", "numAffected": 61, "numAtRisk": 408}]}, {"term": "Upper Respiratory Tract Infection", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 12.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 24, "numAtRisk": 406}, {"groupId": "EG001", "numAffected": 31, "numAtRisk": 408}]}, {"term": "Influenza", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 12.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 30, "numAtRisk": 406}, {"groupId": "EG001", "numAffected": 30, "numAtRisk": 408}]}, {"term": "Urinary Tract Infection", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 12.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 30, "numAtRisk": 406}, {"groupId": "EG001", "numAffected": 17, "numAtRisk": 408}]}, {"term": "Arthralgia", "organSystem": "Musculoskeletal and connective tissue disorders", "sourceVocabulary": "MedDRA 12.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 11, "numAtRisk": 406}, {"groupId": "EG001", "numAffected": 21, "numAtRisk": 408}]}, {"term": "Dizziness", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA 12.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 15, "numAtRisk": 406}, {"groupId": "EG001", "numAffected": 37, "numAtRisk": 408}]}, {"term": "Tremor", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA 12.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 406}, {"groupId": "EG001", "numAffected": 31, "numAtRisk": 408}]}, {"term": "Headache", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA 12.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 21, "numAtRisk": 406}, {"groupId": "EG001", "numAffected": 17, "numAtRisk": 408}]}, {"term": "Hyperhidrosis", "organSystem": "Skin and subcutaneous tissue disorders", "sourceVocabulary": "MedDRA 12.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 5, "numAtRisk": 406}, {"groupId": "EG001", "numAffected": 27, "numAtRisk": 408}]}, {"term": "Hypertension", "organSystem": "Vascular disorders", "sourceVocabulary": "MedDRA 12.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 30, "numAtRisk": 406}, {"groupId": "EG001", "numAffected": 35, "numAtRisk": 408}]}, {"term": "Hypoglycemia", "organSystem": "Endocrine disorders", "sourceVocabulary": "MedDRA 12.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 14, "numAtRisk": 406}, {"groupId": "EG001", "numAffected": 162, "numAtRisk": 408}]}]}, "moreInfoModule": {"limitationsAndCaveats": {"description": "For participants who did not complete 52 weeks LOCF (last observation carried forward) was used."}, "certainAgreement": {"piSponsorEmployee": false, "restrictionType": "OTHER", "restrictiveAgreement": true, "otherDetails": "If an Investigator requests permission to publish data from this study any such publication is to be agreed with AstraZeneca (AZ) in advance. The investigator agrees to provide AZ as soon as possible with drafts of proposed publications. Unless otherwise agreed, AZ shall have a period of 60 days from receipt of the proposed final manuscript to review it and may within such time require that submission for publication of the manuscript be delayed in order for AZ to file patent applications."}, "pointOfContact": {"title": "Eva Johnsson", "organization": "AstraZeneca", "email": "ClinicalTrialTransparency@astrazeneca.com"}}}, "derivedSection": {"miscInfoModule": {"versionHolder": "2024-06-24", "removedCountries": ["Brazil"]}, "conditionBrowseModule": {"meshes": [{"id": "D000003920", "term": "Diabetes Mellitus"}, {"id": "D000003924", "term": "Diabetes Mellitus, Type 2"}], "ancestors": [{"id": "D000044882", "term": "Glucose Metabolism Disorders"}, {"id": "D000008659", "term": "Metabolic Diseases"}, {"id": "D000004700", "term": "Endocrine System Diseases"}], "browseLeaves": [{"id": "M7115", "name": "Diabetes Mellitus", "asFound": "Diabetes", "relevance": "HIGH"}, {"id": "M7119", "name": "Diabetes Mellitus, Type 2", "asFound": "Type 2 Diabetes", "relevance": "HIGH"}, {"id": "M11639", "name": "Metabolic Diseases", "relevance": "LOW"}, {"id": "M25403", "name": "Glucose Metabolism Disorders", "relevance": "LOW"}, {"id": "M7862", "name": "Endocrine System Diseases", "relevance": "LOW"}], "browseBranches": [{"abbrev": "BC18", "name": "Nutritional and Metabolic Diseases"}, {"abbrev": "BC19", "name": "Gland and Hormone Related Diseases"}, {"abbrev": "All", "name": "All Conditions"}]}, "interventionBrowseModule": {"meshes": [{"id": "D000008687", "term": "Metformin"}, {"id": "C000529054", "term": "Dapagliflozin"}, {"id": "D000005913", "term": "Glipizide"}], "ancestors": [{"id": "D000007004", "term": "Hypoglycemic Agents"}, {"id": "D000045505", "term": "Physiological Effects of Drugs"}, {"id": "D000077203", "term": "Sodium-Glucose Transporter 2 Inhibitors"}, {"id": "D000045504", "term": "Molecular Mechanisms of Pharmacological Action"}], "browseLeaves": [{"id": "M11667", "name": "Metformin", "asFound": "Facial", "relevance": "HIGH"}, {"id": "M348449", "name": "Dapagliflozin", "asFound": "Body weight", "relevance": "HIGH"}, {"id": "M9023", "name": "Glipizide", "asFound": "Xylocaine", "relevance": "HIGH"}, {"id": "M10054", "name": "Hypoglycemic Agents", "relevance": "LOW"}, {"id": "M1691", "name": "Sodium-Glucose Transporter 2 Inhibitors", "relevance": "LOW"}], "browseBranches": [{"abbrev": "Hypo", "name": "Hypoglycemic Agents"}, {"abbrev": "All", "name": "All Drugs and Chemicals"}]}}, "hasResults": true}